Last reviewed · How we verify
NCT00480155
A Prospective, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety of A Monovalent Vaccine in Healthy Adults
Phase 2 trial testing Frozen FluMist® in Healthy in 300 participants. Completed in 1 December 2007.
1 December 2007
Quick facts
| Lead sponsor | MedImmune LLC |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 300 |
| Start date | 1 May 2007 |
| Primary completion | 1 December 2007 |
| Estimated completion | 1 December 2007 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Frozen FluMist® — full drug profile →
- Placebo
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
MedImmune LLC — full company profile →
Who can join
Adults 18 to 49, any sex, with Healthy. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
The primary endpoint of this study is fever ≥101°F.
Time frame: Study Days 0-7
Sponsor's own description
To assess the safety of a vaccine in healthy adults prior to the release of the vaccine (FluMist®) containing it.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00480155
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other MedImmune LLC trials
Trials by the same sponsor.
- NCT04145193 — Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC · Phase 2 · withdrawn
- NCT04522323 — A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma · Phase 1 · active not recruiting
- NCT03903718 — Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza · Phase 2 · withdrawn
- NCT04261075 — IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. · Phase 1 · completed
- NCT03889275 — A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00480155 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by MedImmune LLC
- Last refreshed: 19 December 2008
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00480155.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing